Neurocrine Biosciencesvs.Vertex Pharmaceuticals
NBIX vs VRTX · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Vertex Pharmaceuticals is about 8.9× larger than Neurocrine Biosciences by market cap; Neurocrine Biosciences trades at the lower P/E (20.3 vs 29.1); year to date, Vertex Pharmaceuticals leads (+11.5% vs +1.2%).
Side by side
| NBIX | VRTX | |
|---|---|---|
| Market cap | $14.3B | $128B |
| Price | $141.25 | $503.25 |
| Today | −1.5% | −0.5% |
| Return YTD | +1.2% | +11.5% |
| Return 1Y | +4.7% | +23.2% |
| Since June 26, 2026 | −16.2% | +2.4% |
| P/E | 20.3 | 29.1 |
| P/S | 4.3 | 10.2 |
| P/B | 3.9 | 6.3 |
Data as of 2026-10-08 · updates daily after U.S. close
Since June 26, 2026: the change in the closing price, from the daily closes Sectivia records itself since that date.
The two companies
Neurocrine BiosciencesNBIX
Ingrezza for tardive dyskinesia, plus a wider neurology and endocrine portfolio.
Full NBIX profile →Vertex PharmaceuticalsVRTX
Cystic fibrosis medicines carry the business. The newer work sits in pain treatment and in cell and gene therapy, where Casgevy belongs.
Full VRTX profile →More NBIX & VRTX comparisons
Other head-to-heads in the Biotech & innovation segment.